US 7981869
RNAi modulation of RSV and therapeutic uses thereof
granted A61KA61K31/713A61K9/0078
Quick answer
US patent 7981869 (RNAi modulation of RSV and therapeutic uses thereof) held by Alnylam Pharmaceuticals, Inc. expires Mon Jul 14 2031 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Alnylam Pharmaceuticals, Inc.
- Grant date
- Tue Jul 19 2011 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jul 14 2031 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 18
- CPC classes
- A61K, A61K31/713, A61K9/0078, A61P, A61P11/00